[go: up one dir, main page]

DK0567450T3 - Cytokinsyntesehæmmende faktor og fremgangsmåde til anvendelse af samme - Google Patents

Cytokinsyntesehæmmende faktor og fremgangsmåde til anvendelse af samme

Info

Publication number
DK0567450T3
DK0567450T3 DK90911213T DK90911213T DK0567450T3 DK 0567450 T3 DK0567450 T3 DK 0567450T3 DK 90911213 T DK90911213 T DK 90911213T DK 90911213 T DK90911213 T DK 90911213T DK 0567450 T3 DK0567450 T3 DK 0567450T3
Authority
DK
Denmark
Prior art keywords
same
cytokine synthesis
inhibiting factor
cytokine
synthesis inhibiting
Prior art date
Application number
DK90911213T
Other languages
English (en)
Inventor
Timothy R Mosmann
Martha W Bond
Paulo J M Vieira
Kevin W Moore
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK0567450T3 publication Critical patent/DK0567450T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK90911213T 1989-06-28 1990-06-28 Cytokinsyntesehæmmende faktor og fremgangsmåde til anvendelse af samme DK0567450T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37266789A 1989-06-28 1989-06-28
US45395189A 1989-12-20 1989-12-20
PCT/US1990/003554 WO1991000349A1 (en) 1989-06-28 1990-06-28 Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same

Publications (1)

Publication Number Publication Date
DK0567450T3 true DK0567450T3 (da) 1999-12-13

Family

ID=27005854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90911213T DK0567450T3 (da) 1989-06-28 1990-06-28 Cytokinsyntesehæmmende faktor og fremgangsmåde til anvendelse af samme

Country Status (22)

Country Link
EP (2) EP0567450B1 (da)
JP (1) JP2813063B2 (da)
KR (1) KR0183035B1 (da)
CN (3) CN1318589C (da)
AT (1) ATE180833T1 (da)
AU (1) AU635058B2 (da)
CA (1) CA2062763C (da)
CS (1) CS414591A3 (da)
DE (1) DE69033143T2 (da)
DK (1) DK0567450T3 (da)
ES (1) ES2132068T3 (da)
FI (1) FI107926B (da)
GR (1) GR3030404T3 (da)
HK (2) HK1040493B (da)
HU (1) HU216310B (da)
IL (1) IL94878A (da)
NO (1) NO301718B1 (da)
NZ (1) NZ234291A (da)
PT (1) PT94514B (da)
SG (1) SG52282A1 (da)
TW (1) TW218383B (da)
WO (1) WO1991000349A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
EP0567576B1 (en) * 1991-01-16 1995-01-04 Schering Corporation Treatment of neoplastic disease with interleukin-10
US6106823A (en) * 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DK0567586T3 (da) * 1991-01-16 1995-12-04 Schering Corp Anvendelse af interleukin-10 ved adoptiv immunterapi af cancer
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
ES2138976T3 (es) * 1991-08-06 2000-02-01 Schering Corp Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos.
WO1993017698A1 (en) * 1992-03-04 1993-09-16 Schering Corporation Use of interleukin-10 to suppress graft-vs.-host disease
US6884410B1 (en) 1992-03-04 2005-04-26 Schering Corporation Methods for modulating antigen-specific immune responses
US6277635B1 (en) 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
WO1993018783A1 (en) * 1992-03-20 1993-09-30 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
CZ283488B6 (cs) * 1992-08-20 1998-04-15 Schering Corporation Farmaceutický prostředek obsahující IL-4 a/nebo IL-10 nebo protilátky proti IL-4 a IL-10, způsob jeho výroby a jeho použití
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
CA2144648A1 (en) * 1992-09-18 1994-03-31 Mario Clerici Restoration of immunocompetency to t helper cells in hiv infected patients
SG48733A1 (en) * 1992-10-01 1998-05-18 Schering Corp Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
JPH08510719A (ja) * 1993-02-01 1996-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
EP0711346A1 (en) * 1993-07-26 1996-05-15 Schering Corporation Agonists and antagonists of human interleukin-10
US5650060A (en) * 1994-01-28 1997-07-22 Minnesota Mining And Manufacturing Company Ionically conductive agent, system for cathodic protection of galvanically active metals, and method and apparatus for using same
MX9606537A (es) 1994-07-05 1997-12-31 Steeno Res Group As Inmunomoduladores.
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
CN101307106B (zh) * 1995-12-13 2013-06-12 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
WO1997026278A1 (en) * 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
IL126623A0 (en) * 1996-04-17 1999-08-17 Prendergast Patrick T Pharmaceutical compositions and kits for dhea combined therapy
CA2264918A1 (en) * 1996-09-06 1998-03-12 Schering Corporation Method for lowering cholesterol levels
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US6465176B1 (en) * 1998-10-02 2002-10-15 Message Pharmaceuticals, Inc. Method for identifying compounds RNA/RNA binding protein interactions
WO2000073457A1 (en) * 1999-05-27 2000-12-07 Schering-Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
KR20020091170A (ko) 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
WO2011159881A2 (en) 2010-06-16 2011-12-22 Allergan, Inc. Il-10 and methods of treating ocular and other diseases
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183931A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
GB202003428D0 (en) * 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
IE62650B1 (en) * 1989-08-04 1995-02-22 David & Sons Ltd Dispensing apparatus
EP0506836B1 (en) * 1989-12-20 1994-09-28 Schering Corporation BCRF1 PROTEINS AS INHIBITORS OF INTERFERON-$g(g)

Also Published As

Publication number Publication date
NO301718B1 (no) 1997-12-01
CN1317343A (zh) 2001-10-17
DE69033143D1 (de) 1999-07-08
NZ234291A (en) 1992-11-25
HU906705D0 (en) 1992-03-30
AU635058B2 (en) 1993-03-11
CA2062763C (en) 2010-01-05
IL94878A (en) 2003-01-12
PT94514A (pt) 1991-04-18
GR3030404T3 (en) 1999-09-30
ATE180833T1 (de) 1999-06-15
HU216310B (hu) 1999-06-28
WO1991000349A1 (en) 1991-01-10
EP0405980A1 (en) 1991-01-02
JPH04502560A (ja) 1992-05-14
KR920701437A (ko) 1992-08-11
CS414591A3 (en) 1992-12-16
HK1008834A1 (en) 1999-05-21
AU6077090A (en) 1991-01-17
JP2813063B2 (ja) 1998-10-22
TW218383B (da) 1994-01-01
HK1040531A1 (en) 2002-06-14
HK1040493B (zh) 2005-12-16
KR0183035B1 (ko) 1999-04-01
HUT61048A (en) 1992-11-30
DE69033143T2 (de) 1999-10-21
CN1051393A (zh) 1991-05-15
CN1198642C (zh) 2005-04-27
EP0567450B1 (en) 1999-06-02
EP0567450A1 (en) 1993-11-03
CN1317569A (zh) 2001-10-17
CN1318589C (zh) 2007-05-30
HK1040493A1 (en) 2002-06-14
HK1040531B (zh) 2008-01-11
ES2132068T3 (es) 1999-08-16
FI107926B (fi) 2001-10-31
SG52282A1 (en) 1998-09-28
NO915115D0 (no) 1991-12-27
PT94514B (pt) 1998-02-27
FI916126A0 (fi) 1991-12-27
CA2062763A1 (en) 1990-12-29
IL94878A0 (en) 1991-04-15
NO915115L (no) 1992-02-26

Similar Documents

Publication Publication Date Title
DK0567450T3 (da) Cytokinsyntesehæmmende faktor og fremgangsmåde til anvendelse af samme
DK0504177T3 (da) IL-11, et pattedyrcytokin
DK0409113T3 (da) Muteiner af humant erythropoietin, deres fremstilling og anvendelse
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
DK20690A (da) Alkoxy-1,2,4-triazolo(1,5-c)pyrimidin-2-sulfonamider, fremgangsmaade til deres fremstilling og mellemprodukter
ES2123515T3 (es) Antagonistas de citoquinas a base de proteinas virales aisladas.
DE69013011D1 (de) Bcrf1-proteine als inhibitoren von interferon-g(g).
ATE218800T1 (de) Hufeisen
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
RU94045821A (ru) Трансгенные растения, проявляющие множественную устойчивость к вирусу, и способ их получения
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi
DK98386D0 (da) Fremgangsmaade og mellemprodukter til fremstilling af 4-alkoxy-6-alkyl-2-cyanamino-1,3,5-triaziner samt mellemprodukternes fremstilling
DK403181A (da) Fremgangsmaade til fremstilling af n-(4-( ( (1,4-diamino-6-pteridinyl) methyl) methylamino) benzoyl) glutaminsyre og analoge dertil
IT8017714A0 (it) Sistema di composizione di basi disostegno per piani di bauli, scrivanie e simili,con lastre di marmo
IT8602910A0 (it) Metodo per la produzione e messa in opera rapida di tappeto erboso rimovibile.
SE8704006D0 (sv) Bildvisningsanordning